Systematic literature review compares long-term effectiveness of nintedanib and pirfenidone in idiopathic pulmonary fibrosis, highlighting real-world outcomes.
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease. Pirfenidone and nintedanib slow progression, but no head-to-head randomized trials have tested their long-term effectiveness, particularly in real-world and advanced disease.
No takes yet. Share an insight, caveat, or question.
Ginés Sanz Romero (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: